Promising combo for tough prostate cancer hits snag, study halted
NCT ID NCT03360721
First seen Feb 11, 2026 · Last updated May 19, 2026 · Updated 12 times
Summary
This study tested a combination of two drugs, apalutamide and abiraterone, along with prednisone, in men with a type of advanced prostate cancer that no longer responds to standard hormone therapy. The goal was to see if this drug combo could slow cancer growth. Only 7 people enrolled before the study was stopped early. Participants had to have cancer that spread and a specific genetic marker.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IVB PROSTATE CANCER AJCC V8 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.